Skip to main content
. Author manuscript; available in PMC: 2022 Jul 6.
Published in final edited form as: J Adolesc Health. 2019 Nov 19;66(1):100–106. doi: 10.1016/j.jadohealth.2019.07.022

Table 2.

Key parameter estimates used in cost-effectiveness analyses

Parameter Base-case value Sensitivity range Source Distributions
Annual PrEP cost ($) 12,376 5,452–17,137 Juusola 2012 [15], Chen 2014 [16] Gamma (α = 4, β = 2,853)
Lifetime treatment cost saved per case of HIV averted ($)a 478,142 382,170–478,142 Farnham 2013 [20], Hutchinson 2006 [21] Gamma (α = 50, β = 9,632)
QALYs gained per case of HIV averteda 4.45 4.45–6.43 Farnham 2013 [20], Hutchinson 2010 [22] Gamma (α = 10, β = .4)
Lifetime probability of an 18-year-old not getting infected
 Black ASMM .592 .591–.644 Calculated based on estimates from Hess 2017 [23] Beta (α = 7, β = 5)
 White ASMM .916 .914–.917 Calculated based on estimates from Hess 2017 [23] Beta (α = 55, β = 5)

ASMM = adolescent sexual minority males; PrEP = pre-exposure prophylaxis; QALY = quality-adjusted life years.

a

Lifetime HIV treatment costs saved and QALYs gained per case of infection averted were discounted. All costs were in 2017 dollars.